Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Trial Profile

Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Folinic acid; Folinic acid; Methotrexate; Methylprednisolone; Rituximab; Vincristine
  • Indications Acute lymphoblastic leukaemia; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jul 2017 Planned number of patients changed from 18 to 21.
    • 05 Jul 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2018.
    • 05 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top